|
Modulation of the hypothalamic-pituitary-gonadal axis in rats with polycystic ovary syndrome (PCOS) due to treatment with linagliptin
|
Farangis Ghasemi   , Nawal Abbas Attia Al-Khlifawi |
|
|
|
Abstract: (265 Views) |
Introduction: One of the complications of polycystic ovary syndrome (PCOS) is abnormal levels of sex hormones in serum. Hyperglycemia can be seen in chronic PCOS. Therefore, the effect of linagliptin as an antidiabetic drug on the changes in sex hormones in PCOS rats was investigated.
Methods and Materials: This research was conducted on 40 adult female rats (220-200g), except the control group, the rest were induced PCOS by taking letrozole orally. PCOS rats were divided into the untreated group, a treated group with metformin 500 mg/kg/bw, and two groups treated with doses of 4 and 8 mg/kg/bw of linagliptin solution. After 40 days, the rats were anesthetized by intraperitoneal injection of a mixture of ketamine hydrochloride and xylazine hydrochloride, and blood was taken from their hearts. The investigated serum parameters were measured. The resulting data were analyzed with appropriate tests and groups were compared.
Results: The findings indicated an increase in sugar, weight, and lutein and testosterone hormones in all PCOS mice compared to the control group, which showed a significant decrease (p<0.5) in the groups treated with metformin and linagliptin compared to the untreated PCOS group. A significant increase was also observed in the serum levels of follicle-stimulating hormone and progesterone in the groups treated with both drugs compared to the untreated group. The modulating effect of metformin was not significantly different from the higher dose of linagliptin. Taking these two drugs reduced significantly the increase of blood glucose and weight in the treatment groups compared to PCOS rats without treatment.
Conclusion: The results showed that linagliptin, with its positive effect on the hormones of the pituitary-ovarian axis, moderates some complications caused by polycystic ovary syndrome, such as the increase of blood glucose and weight, which are the reason for other complications of this syndrome.
|
|
| Keywords: Estrogen, Gonadotropin, Linagliptin, Metformin, Weight |
|
|
Full-Text [PDF 252 kb]
(65 Downloads)
|
Type of Study: Research |
Subject:
General
Received: 2023/12/15 | Accepted: 2023/08/23 | Published: 2023/08/23
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
